artemether 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antimalarial agents, artemisinin related compounds | 245 | 71963-77-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An artemisinin derivative that is used in the treatment of MALARIA.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.28 | g | O |
| 0.12 | g | P |
| 0.28 | g | R |
| 0.28 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 6.70 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 58 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| S (Water solubility) | 0.46 mg/mL | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 7, 2009 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P01BE02 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Artemisinin and derivatives, plain |
| ATC | P01BF01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Artemisinin and derivatives, combinations |
| FDA EPC | N0000175482 | Antimalarial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000962 | Antimalarials |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| CHEBI has role | CHEBI:38068 | antimalarials |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chloroquine Resistant Plasmodium Falciparum Malaria | indication | ||
| Torsades de pointes | contraindication | 31722008 | |
| Hypokalemia | contraindication | 43339004 | |
| Bradycardia | contraindication | 48867003 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Hypomagnesemia | contraindication | 190855004 | |
| Congenital long QT syndrome | contraindication | 442917000 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4028721 | VUID |
| N0000178417 | NUI |
| D02483 | KEGG_DRUG |
| 18343 | RXNORM |
| C0052429 | UMLSCUI |
| CHEBI:195280 | CHEBI |
| D8Z | PDB_CHEM_ID |
| CHEMBL566534 | ChEMBL_ID |
| DB06697 | DRUGBANK_ID |
| D000077549 | MESH_DESCRIPTOR_UI |
| 68911 | PUBCHEM_CID |
| 9955 | IUPHAR_LIGAND_ID |
| 6458 | INN_ID |
| C7D6T3H22J | UNII |
| 18572 | MMSL |
| d05142 | MMSL |
| 420578008 | SNOMEDCT_US |
| 420661005 | SNOMEDCT_US |
| 4028721 | VANDF |
| 009714 | NDDF |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0078-0568 | TABLET | 20 mg | ORAL | NDA | 28 sections |
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0078-0568 | TABLET | 20 mg | ORAL | NDA | 28 sections |
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0078-0568 | TABLET | 20 mg | ORAL | NDA | 28 sections |
| COARTEM | HUMAN PRESCRIPTION DRUG LABEL | 2 | 76413-154 | TABLET | 20 mg | ORAL | NDA | 27 sections |